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Summary Testicular function was studied in 40 males treated in childhood for Hodgkin's disease at St
Bartholomew's Hospital, and the Hospital for Sick Children, London, between 1971-1985. All patients were
16 years or over at evaluation, and off treatment more than 6 years. Basal FSH, LH and testosterone levels
were measured. Testicular size was measured using a Prader orchidometer, and all patients were offered a
seminal analysis. Twenty-eight patients were treated with chemotherapy, usually ChlVPP. Twenty-one also had
radiotherapy, five below the diaphragm. Twelve patients were treated with radiotherapy alone (five below the
diaphragm). Twenty-six of 28 patients treated with chemotherapy and three of five patients treated with
radiotherapy alone below the diaphragm have elevated basal FSH levels, and 18 of these also have elevated
basal LH levels. Median testicular volume is 11 ml (range 5-25 ml). Eleven of 13 patients investigated are
azoospermic. All patients have normal testosterone levels, and normal secondary sexual characteristics. There
is no biochemical evidence of healing of the damaged germinal epithelium with elevated FSH levels-persisting
up to 17 years from the end of therapy. These results indicate a high incidence of damage to the germinal
epithelium in patients treated with ChlVPP chemotherapy and/or radiotherapy below the diaphragm. Appro-
priate counselling of these patients with regard to their reproductive capabilities is essential.
With a current 5 year event free survival of 90%, there is
increasing interest in the late effects of treatment in patients
with Hodgkin's disease. Decreased sitting height due to
extended field irradiation including the spine (Wilimas et al.,
1980) and abnormalities of thyroid function after neck
radiotherapy have been well documented (Shalet et al., 1977).
Infertility appears to be almost inevitable in adult males with
Hodgkin's disease treated by six or more courses of MOPP
or MVPP (mustine, vincristine/vinblastine, procarbazine,
prednisolone) (Whitehead et al., 1982a). Chemotherapy
induced testicular damage in patients treated for Hodgkin's
disease in childhood was first reported by Sherins et al., in
1978. Whitehead et al. (1982b) reported 15 males treated with
MOPP for Hodgkin's disease in childhood and concluded
that severe testicular damage is common, with azoospermia,
but normal pubertal development. More recently Bramswig
et al. (1990) evaluated testicular function in 75 boys treated
for Hodgkin's disease with involved or extended field irradia-
tion and chemotherapy with OPPA (vincristine, prednisone,
procarbazine, doxorubicin) or COPP (cyclophosphamide,
vincristine, prednisone, procarbazine). Testicular dysfunction
was observed in boys treated before as well as during
puberty. Abnormal basal FSH/LH levels were found more
frequently in patients who had received higher cumulative
doses of chemotherapy.
We have studied testicular function in 40 males treated
in childhood for Hodgkin's disease with chemotherapy
(usually chlorambucil, vincristine, procarbazine, prednisolone
- ChlVPP) (Robinson et al., 1984) and/or radiotherapy to
assess the effect of this treatment on subsequent fertility.
Method
Testicular function was evaluated in males treated for Hodg-
kin's disease in childhood at St Bartholomew's Hospital and
the Hospital for Sick Children, London, between 1971 and
1985. All patients included in the study were 16 years or over
(median 23 years, range 16 years 8 months-30 years) at the
time of their most recent evaluation and had been off treat-
ment for a minimum of 6 years (median 11 years 9 months,
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range 6-18 years). Basal FSH, LH and testosterone levels
were measured. FSH and LH levels were measured by stan-
dard immunoradiometric assays with intra- inter-assay
coefficient of variation (CV) of <5% for both assays. Testo-
sterone was measured by radioimmunoassay with a CV of
<5%. Testicular size was measured using a Prader
orchidometer, and all patients were given the opportunity to
have a seminal analysis performed.
For the purpose of this study we defined abnormal tes-
ticular function using the following criteria. Germ cell dys-
function was considered present ifbasal FSH level was raised
above 8 u l-1'. Confirmatory evidence for this was a low
testicular volume (<15ml, Zachmann et al., 1974), and a
low sperm count. Leydig cell dysfunction was considered
present if basal LH level was raised above 10ul-' with or
without a low testosterone level (<9nmoll1').
Clinical details
Seventy-five males were treated for Hodgkin's disease
between 1971-1985, 45 at St Bartholomew's Hospital and 30
at the Hospital for Sick Children. Fifteen patients have died,
nine have been lost to follow up, six are followed up at other
hospitals, and five are still under 16 years of age. Forty
patients are over the age of 16 years and have been off
treatment for more than 6 years. These patients form the
study population. Patient characteristics are shown in Table
I.
Of the 28 patients who were treated with chemotherapy, 22
received ChlVPP (median six courses, range 3-8) and five
patients treated between 1971 and 1976 had MOPP or MVPP
chemotherapy (median six courses, range 3-20). One patient
was treated with six courses of COPP. The median dose and
range of drugs known to be toxic to the gonads is shown in
Table II. Three patients received additional chemotherapy
with ABVD (doxorubicin, bleomycin, vinblastine and DTIC),
and one of these also had two courses of PAVE (pred-
nisolone, doxorubicin, vinblastine and etoposide) and four
courses of CCNU, chlorambucil and etoposide for resistant
disease.
Five patients who had chemotherapy also had radio-
therapy below the diaphragm (two to para aortic glands,
2,250 and 2,500 cGy; one inverted Y, 2,750 cGy; one coeliac
axis, 2,500cGy; and one whole abdomen after abdominal
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median 10 yrs 5 m'ths
(range 4 yrs 3 m'ths- 15 yrs 11 m'ths)
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Table II Median dose m2 of drugs with known gonadal toxicity
(range)
CCNU 600mgm-2
Chlorambucil 504mgm-2 (242-760)
Cyclophosphamide 6,310mgm-2
Mustine 72mgm-2 (36-240)
Procarbazine 8,000mg m-2 (500-33,600)
relapse, 3,500 cGy). Twelve patients were treated with
radiotherapy alone, seven above the diaphragm, four below
the diaphragm, and one above and below the diaphragm.
Results
Chemotherapy
Twenty-six of 28 patients who had chemotherapy have
elevated basal FSH levels, with a median of 18.1 u 1-', range
10.1-35.6 u 1- (upper limit of normal 8 uI`). One patient
has a normal FSH level after only three courses of ChlVPP
at the age of 4 years 10 months and one patient has not had
FSH/LH and testosterone levels measured. Eighteen patients
have had serial FSH levels measured at least 12 months off
treatment and over a minimum of 2 years, and maximum of
13 years (Table III). FSH levels remain elevated for up to 17
years from the end of therapy. In no patient has an elevated
FSH level returned to normal. Three patients (1, 4, 8: Table
III) had FSH levels measured before or during puberty and
more than 1 year off treatment. All had normal levels which
subsequently became elevated post puberty (Figure 1).
Sixteen patients also have elevated basal LH levels greater
than 10.0 u l-1, with a median of 12.3 u 1-, range
10.1-24.0 u l-' (upper limit of normal lOu l-1). Eighteen
patients have had serial LH measurements (Table III). Four
patients (case numbers 4, 7, 12, 15) have always had normal
levels. Two patients (2, 18) initially had elevated LH levels 2
years and 4 years 6 months off treatment respectively, which
subsequently returned to normal. Four patients (3, 5, 9, 17)
have had persistently elevated levels and eight patients (1, 6,
8, 10, 11, 13, 14, 16) all except one of whom (1) were post
pubertal, initially had normal LH levels which have subse-
quently become elevated with increasing time from the end of
treatment (Figure 2). Testerone level is normal in all 25
patients in whom it was measured (median 14.5 nmol [1,
range 8-30 nmol 1-). Whilst all testosterone levels remain in
the normal range, three patients have shown post pubertally
Figure 1
damage
elevated
Basal FSH levels pre and post puberty illustrating that
to the seminiferous epithelium, as indicated by an
FSH level, may only become apparent post puberty.
a sustained fall in testosterone level over 4 years (Table III,
10), 7 years (Table III, 15) and 12 years (Table III, 13) which
in two patients (10, 13) has been associated with a rise in
previously normal LH levels. Five other patients may be
demonstrating a similar trend (Table III, 3, 5, 8, 16, 18).
The median testicular volume for 27 patients is 11 ml
(range 5-25 ml). Seventeen patients have testicular volumes
of 12 ml or less. So far only 12 patients have had a seminal
analysis performed, and 11 are azoospermic after a median
of six courses of Ch1VPP (range 3-8) and a median of 10
years (range 3 years 6 months- 15 years) off treatment. The
patient who is infertile after only three courses of ChlVPP
was treated at the age of 13 years and did not receive any
abdominal radiotherapy (Table III, 13). All of these 11
patients have raised FSH levels, 7/11 also have raised LH
levels, and 7/11 have testicular volumes of 12 ml or less. One
patient is severely oligospermic with a sperm count of
0.4 x 106 ml-', and 49% abnormal forms, 4 years following
treatment with four courses of ChlVPP and six courses of
ABVD. His FSH level is elevated, but LH and testosterone
levels and testicular volumes are normal. Nevertheless, this
patient has fathered two sons 5 and 6 years off treatment
(Table III, 15). Another patient has a baby daughter 11 years
after treatment with ChlVPP x 6, but FSH/LH, testosterone
levels, and testicular volumes are not available on this
patient. However, as Schwartz (1990) pointed out, the
reported fathering of a child is not necessarily conclusive
proof of fertility. None of the other patients have children.
Radiotherapy
Of 12 patients who were treated with radiotherapy alone,
seven had radiotherapy to sites above the diaphragm, and all
have normal FSH, LH and testosterone levels, and normal
testicular volumes. One patient who requested a seminal
analysis has a normal sperm count.
Four patients had radiotherapy alone to sites below the
diaphragm and one patient had radiotherapy above and
below the diaphragm. Three patients received 3,500 cGy to
an inverted Y field, all have elevated FSH levels and two
have elevated LH levels. One of these patients initially had a
normal FSH level which became elevated during puberty
(Figure 1). Testosterone levels are normal, but all patients
have small testes - 12 ml or less. One patient has had a
seminal analysis and he is severely oligospermic with a sperm
Table I Patient characterstics
Age at diagnosis
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Figure 2 Rise in basal LH levels with increasing time from the
end of therapy.
count of 0.4 x 106 m1 ', 16 years off treatment. Two patients
received 3,500 cGy to the right groin. Both have normal
FSH, LH and testosterone levels, but one has small testes
(8 ml, 10 ml). For nine of the total of ten patients who
received radiotherapy below the diaphragm (five patients
treated by radiotherapy alone and five treated by a combina-
tion of radiotherapy and chemotherapy), it is not possible to
estimate the dose to the testes which are out of the primary
beam and further protected by a scrotal lead shield. How-
ever, one patient treated with radiotherapy alone, 3,500 cGy
to an inverted Y field with a further 500 cGy to the right
inguinal region, had a measured total scrotal dose of456cGy
in 20 fractions over 28 days. At that time he had bilaterally
undescended testes and subsequently had a right orchid-
opexy. Testicular volumes are 2 ml right and 10ml left.
Discussion
A number of previous studies have reported on reproductive
function following treatment for Hodgkin's disease in child-
hood with MOPP (Whitehead et al., 1982b; Ortin et al.,
1990) and OPPA/COPP (Bramswig et al., 1990).
We have reported here 40 males treated for Hodgkin's
disease, 28 of whom received combination chemotherapy,
mostly ChlVPP. Of these 28 patients, 26 (93%) have elevated
basal FSH levels, indicating damage to seminiferous tubules.
Seventeen of 27 patients have testicular volumes 12 ml or
less, indicating reduced testicular size, normal adult testicular
volume being equal to or greater than 15 ml (Zachmann et
al., 1974). Eleven of 12 patients who have had a seminal
analysis are azoospermic, the other patient being oligosper-
mic. This indicates a high incidence of damage to the ger-
minal epithelium in patients treated with this regimen, both
before or during puberty. The only patient who does not
appear to have any impairment of gonadal function received
only three courses of ChlVPP at the age of 4 years 10
months.
The damage caused to the gonad is not just a function of
the chemotherapy received. Three of five patients treated
with radiotherapy alone, below the diaphragm, have evidence
of impairment of gonadal function as shown by elevated
FSH levels in three associated with elevated LH levels in two
patients. All three have small testes and one who has had a
seminal analysis is oligospermic, 16 years off treatment.
There is no evidence of recovery of function up to 17 years
from diagnosis. This is similar to the Stanford experience
(Ortin et al., 1990).
All patients treated with chemotherapy and/or radio-
therapy below the diaphragm having been advised of the
possibility of infertility were given the opportunity to have a
seminal analysis. However, only 13 patients so far have
undergone this investigation. The remainder do not wish to
know their fertility status at the present time. The desire for
information was not related to the age of the patient as the
median age of the two groups is the same.
All patients with azoospermia or oligospermia have raised
FSH levels, confirming the close correlation between raised
FSH levels and germ cell damage (Briimswig et al., 1990;
Siimes & Rautonen, 1990).
This study includes 18 patients who have had serial FSH
and LH measurements. It has been suggested that serial FSH
levels might help to determine whether the damage sustained
by the germinal cell epithelium is in the process of healing
(FSH decreasing), stable, or progressive (FSH increasing)
(Schwartz, 1990). If basal FSH truly reflects damage to the
germinal cell epithelium, then the results shown in Table III
do not give grounds for optimism regarding healing of
chemotherapy induced damage, with elevated levels persisting
up to 17 years from cessation of treatment, suggesting that
the damage to the germinal epithelium is irreversible. Figure
1 demonstrates graphically that FSH levels are unhelpful in
predicting testicular damage in pre pubertal and peripubertal
boys, confirming the findings of Green et al. (1981).
All the patients in the study progressed through puberty
satisfactorily with the normal development of secondary sex-
ual characteristics which would indicate normal Leydig cell
function at that time. None of the patients had gynaecomas-
tia unlike the boys in Sherins study (Sherins et al., 1978).
However, 16/28 treated with chemotherapy and 2/5 treated
with radiotherapy alone (inverted Y 3,500 cGy) have elevated
serum LH levels, first noted 5-19 years from diagnosis. As
all testosterone levels are in the normal range, this suggests
that increased LH secretion is necessary to maintain normal
testosterone production. However with the fall in tes-
tosterone levels noted in several patients, premature Leydig
cell failure is a real possibility. Continuing follow up of these
patients with annual measurement of FSH/LH and tes-
tosterone levels is needed to further elucidate the natural
history of the impairment of gonadal function.
Appropriate counselling of boys treated with ChlVPP
chemotherapy and/or radiotherapy below the diaphragm
with regard to their reproductive potential is essential. How-
ever, it is important to remember that FSH levels in pre- and
peri-pubertal boys are unreliable as indicators of gonadal
damage. Although FSH level and testicular size in patients
who are post pubertal may give a good indication of damage
to the germinal epithelium, seminal analysis still remains the
definitive test of an individual's reproductive potential.
Annual follow up, for many years, will be needed before
the consequences of ChlVPP-induced damage are fully
revealed. There is an urgent need for chemotherapy regimens
effective in Hodgkin's disease which are less damaging to the
gonads.
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